Compare BRT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRT | TTRX |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 298.8M |
| IPO Year | 1994 | 2025 |
| Metric | BRT | TTRX |
|---|---|---|
| Price | $14.08 | $14.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.75 | $8.00 |
| AVG Volume (30 Days) | 31.3K | ★ 69.8K |
| Earning Date | 05-08-2026 | 05-31-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $2.57 |
| 52 Week High | $16.69 | $14.39 |
| Indicator | BRT | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.